Clinical trial registration, sponsored by University of British Columbia, registered 1 Oct 2026.
Phase 2 · not yet recruiting · n = 3
Tags: Registry, Psilocybin, Addiction.
New registrations include psilocybin for methamphetamine use disorder, borderline personality disorder, nicotine craving and premenstrual dysphoric disorder, and a National Institute on Aging trial pairing psilocybin with cognitive training. Results were posted for psilocybin in depression and anxiety in Parkinson's disease.
How much weight it carries: Registrations show what is being attempted, not what was found. (Registry, Plans, not results)
newly registered at UBC: a 25 mg psilocybin dose with repeat fMRI craving scans in nicotine dependence
How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)